Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 491-497

  Carcereny, Enric ^a   Ramirez, Jose Luis ^a   Sanchez Ronco, Maria ^b   Isla, Dolores ^c   Cobo, Manuel ^d   Moran, Teresa ^a   de Aguirre, Itziar ^a   Okamoto, Tatsuro ^a   Wei, Jia ^a,e   Provencio, Mariano ^f   Lopez Vivanco, Guillermo ^g   Camps, Carlos ^h   Domine, Manuel ⁱ   Alberola, Vicente ^j   Sanchez, Jose Miguel ^k   Massuti, Bartomeu ^l   Mendez, Pedro ^a   Taron, Miquel ^a,m   Rosell, Rafael ^a,m  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j HOSPITAL ARNAU DE VILANOVA   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^m INSTITUT UNIVERSITARI DEXEUS   (Spain)

more..

Author keywords

Chemotherapy; CHRNA genes; Nicotinic acetylcholine receptors; Non small cell lung cancer; Single nucleotide polymorphism

Indexed keywords

CISPLATIN; DNA; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3; NICOTINIC RECEPTOR ALPHA5; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; NICOTINIC RECEPTOR SUBUNIT ALPHA3; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATION; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROCEDURES; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENDONUCLEASES; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; SURVIVAL ANALYSIS; TAXOIDS;

EID: 77952553157     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.004     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
2. Hecht S.S. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 2008, 21:160-171.
3. Rosell R., Mendez P., Isla D., Taron M. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007, 2:1063-1066.
4. Minna J.D. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest 2003, 111:31-33.
5. West K.A., Brognard J., Clark A.S., Linnoila I.R., Yang X., Swain S.M., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003, 111:81-90.
6. Song P., Sekhon H.S., Fu X.W., Maier M., Jia Y., Duan J., et al. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Res 2008, 68:4693-4700.
7. Mai H., May W.S., Gao F., Jin Z., Deng X. A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 2003, 278:1886-1891.
8. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001, 7:833-839.
9. Heeschen C., Weis M., Aicher A., Dimmeler S., Cooke J.P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002, 110:527-536.
10. Maneckjee R., Minna J.D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci USA 1990, 87:3294-3298.
11. Schuller H.M. Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. Biochem Pharmacol 1989, 38:3439-3442.
12. Jin Z., Gao F., Flagg T., Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem 2004, 279:23837-23844.
13. Jin Z., Gao F., Flagg T., Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004, 279:40209-40219.
14. Heusch W.L., Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998, 19:551-556.
15. Xin M., Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 2005, 280:10781-10789.
16. Dasgupta P., Kinkade R., Joshi B., Decook C., Haura E., Chellappan S. Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and surviving. Proc Natl Acad Sci USA 2006, 103:6332-6337.
17. Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatr 2008, 13:368-373.
18. Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40:616-622.
19. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
20. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
21. Bierut L.J., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O.F., et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 2007, 16:24-35.
22. Le Marchand L., Derby K.S., Murphy S.E., Hecht S.S., Hatsukami D., Carmella S.G., et al. Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 2008, 68:9137-9140.
23. Shiraishi K., Kohno T., Kunitoh H., Watanabe S., Goto K., Nishiwaki Y., et al. Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis 2009, 30:65-70.
24. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
25. Schuller H.M. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors?. Nat Rev Cancer 2009, 9:195-205.
26. O'Connell J.P., Kris M.G., Gralla R.J., Groshen S., Trust A., Fiore J.J., et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986, 4:1604-1614.
27. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1626.
28. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1.052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
29. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
30. Hoang T., Xu R., Schiller J.H., Bonomi P., Johnson D.H. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005, 23:175-183.
31. Bosken C.H., Wei Q., Amos C.I., Spitz M.R. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002, 94:1091-1099.
32. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
33. Taron M., Alberola V., Lopez-Vivanco G., Camps C., de las Penas R., Alonso G., et al. Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p): a Spanish Lung Cancer Group study. J Clin Oncol 2006, 24(Suppl):377s. [abstr 7053].
34. Luo Z.G., Wang Q., Zhou J.Z., Wang J., Luo Z., Liu M., et al. Regulation of AChR clustering by Dishevelled interacting with MuSK and PAK1. Neuron 2002, 35:489-505.
35. Wang J., Jing Z., Zhang L., Zhou G., Braun J., Yao Y., et al. Regulation of acetylcholine receptor clustering by the tumor suppressor APC. Nat Neurosci 2003, 6:1017-1018.
36. Lam D.C., Girard L., Ramirez R., Chau W.S., Suen W.S., Sheridan S., et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007, 67:4638-4647.
37. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
38. Malanga D., Scrima M., De Marco C., Fabiani F., De Rosa N., De Gisi S., et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008, 7:665-669.
39. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986-3997.